Objectives: The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem non-susceptible pathogens. Methods: To explore relebactam\u27s safety, tolerability and efficacy, we conducted a randomized (1:1:1), controlled, Phase 2 trial
Sims, Matthew
core
Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant <i>Enterobacterales</i> Bloodstream Infections. [PDF]
Wang X +10 more
europepmc +1 more source
Activity of aztreonam-avibactam and comparators against difficult-to-treat resistant Enterobacterales from United States medical centres (2020-24) <sup>†</sup>. [PDF]
Sader HS +4 more
europepmc +1 more source
Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K.
Xiaobing Chu +11 more
core +1 more source
In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli. [PDF]
Karlowsky JA +5 more
europepmc +1 more source
Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study. [PDF]
Young K +6 more
europepmc +1 more source
A Ten-Year Trend of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> From United States Medical Centers: Results From the INFORM Surveillance Program (2015-2024). [PDF]
Sader HS +4 more
europepmc +1 more source
In vitro activity of β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with aztreonam against metallo-β-lactamase producing Escherichia coli clinical isolates. [PDF]
Viguier C +6 more
europepmc +1 more source
Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies. [PDF]
Hernández-García M +8 more
europepmc +1 more source
Molecular determinants associated with resistance to imipenem and imipenem-relebactam in clinical Pseudomonas aeruginosa isolates. [PDF]
Lorusso AB +6 more
europepmc +1 more source

